145 related articles for article (PubMed ID: 26306942)
1. Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.
Jose S; Quinn K; Dunn D; Cox A; Sabin C; Fidler S;
HIV Med; 2016 May; 17(5):368-72. PubMed ID: 26306942
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
[TBL] [Abstract][Full Text] [Related]
3. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
[TBL] [Abstract][Full Text] [Related]
4. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
5. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
6. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
Lodi S; Phillips A; Fidler S; Hawkins D; Gilson R; McLean K; Fisher M; Post F; Johnson AM; Walker-Nthenda L; Dunn D; Porter K;
PLoS One; 2013; 8(9):e75608. PubMed ID: 24086588
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
9. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
10. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
12. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
13. Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study.
Kayigamba FR; Franke MF; Bakker MI; Rodriguez CA; Bagiruwigize E; Wit FW; Rich ML; Schim van der Loeff MF
PLoS One; 2016; 11(7):e0159446. PubMed ID: 27438000
[TBL] [Abstract][Full Text] [Related]
14. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
Hoffmann CJ; Maritz J; van Zyl GU
Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy.
Stratov I; Kent SJ
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):253-9. PubMed ID: 25139203
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
[TBL] [Abstract][Full Text] [Related]
17. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
18. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
[TBL] [Abstract][Full Text] [Related]
19. A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort.
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):772-81. PubMed ID: 27030657
[TBL] [Abstract][Full Text] [Related]
20. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
